Eisai Inc patents expiration
1. Aricept patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6140321 | EISAI INC | Polymorphs of donepezil hydrochloride and process for production |
Dec, 2016
(7 years ago) | |
| US5985864 | EISAI INC | Polymorphs of donepezil hydrochloride and process for production |
Dec, 2016
(7 years ago) | |
| US6245911 | EISAI INC | Donepezil polycrystals and process for producing the same |
Dec, 2018
(5 years ago) | |
| US8481565 | EISAI INC | Method for stabilizing anti-dementia drug |
Oct, 2026
(2 years from now) | |
Drugs and Companies using DONEPEZIL HYDROCHLORIDE ingredient
Market Authorisation Date: 25 November, 1996
Treatment: NA
Dosage: TABLET;ORAL
ARICEPT family patents
2. Aricept Odt patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7727552 | EISAI INC | Oral pharmaceutical preparations decreased in bitterness by masking |
Mar, 2018
(6 years ago) | |
| US7727548 | EISAI INC | Rapidly disintegrable tablet containing polyvinyl alcohol |
Jun, 2022
(1 year, 9 months ago) | |
Drugs and Companies using DONEPEZIL HYDROCHLORIDE ingredient
Market Authorisation Date: 18 October, 2004
Treatment: Administration of approved product for treatment of alzheimer's disease
Dosage: TABLET, ORALLY DISINTEGRATING;ORAL
ARICEPT ODT family patents
3. Banzel patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6740669 | EISAI INC | Crystal modification of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and its use as antiepileptic |
Nov, 2022
(1 year, 5 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8076362 | EISAI INC | Crystal modification A of 1-(2,6-difluorobenzyI)-1 H-1,2,3-triazole-4-carboxamide and dosage forms and formulations thereof |
Jun, 2018
(5 years ago) | |
| US7750028 | EISAI INC | Crystal modifications of 1-(2,6-difluorobenzyl)-1H-1, 2,3-triazole-4-carboxamide |
Oct, 2018
(5 years ago) | |
|
US8076362 (Pediatric) | EISAI INC | Crystal modification A of 1-(2,6-difluorobenzyI)-1 H-1,2,3-triazole-4-carboxamide and dosage forms and formulations thereof |
Dec, 2018
(5 years ago) | |
|
US7750028 (Pediatric) | EISAI INC | Crystal modifications of 1-(2,6-difluorobenzyl)-1H-1, 2,3-triazole-4-carboxamide |
Apr, 2019
(5 years ago) | |
|
US6740669 (Pediatric) | EISAI INC | Crystal modification of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and its use as antiepileptic |
May, 2023
(11 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | May 14, 2016 |
| New Chemical Entity Exclusivity(NCE) | Nov 14, 2013 |
| Orphan Drug Exclusivity(ODE) | Nov 14, 2015 |
Drugs and Companies using RUFINAMIDE ingredient
NCE-1 date: 15 May, 2015
Market Authorisation Date: 14 November, 2008
Treatment: Treatment of epilepsy
Dosage: TABLET;ORAL; SUSPENSION;ORAL
BANZEL family patents
4. Belviq patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8367657 | EISAI INC | Processes for preparing 3-benzazepines |
Apr, 2023
(1 year, 10 days ago) | |
| US6953787 | EISAI INC | 5HT2C receptor modulators |
Apr, 2023
(1 year, 10 days ago) | |
| US8546379 | EISAI INC | 5HT2C receptor modulators |
Apr, 2023
(1 year, 10 days ago) | |
| US7977329 | EISAI INC | 5HT2C receptor modulators |
Apr, 2023
(1 year, 10 days ago) | |
| US8697686 | EISAI INC | Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-thtrahydro-1H-3-benzazepine hydrochloride |
Dec, 2025
(1 year, 8 months from now) | |
| US8168624 | EISAI INC | Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride |
Apr, 2029
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8575149 | EISAI INC | 5HT2C receptor modulators |
Apr, 2023
(1 year, 10 days ago) | |
| US8207158 | EISAI INC | 5HT2c receptor modulators |
Apr, 2023
(1 year, 10 days ago) | |
| US8273734 | EISAI INC | 5HT2C receptor modulators |
Apr, 2023
(1 year, 10 days ago) | |
| US7514422 | EISAI INC | 5HT2c receptor modulators |
Apr, 2023
(1 year, 10 days ago) | |
| US7169401 | EISAI INC | Topical skin care composition containing refined peanut oil |
Jul, 2023
(9 months ago) | |
| US8946207 | EISAI INC | Processes for preparing 3-benzazepines |
Jun, 2024
(a month from now) | |
| US8980881 | EISAI INC | Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride |
Dec, 2025
(1 year, 8 months from now) | |
| US9770455 | EISAI INC | Administration of an anti-obesity compound to individuals with renal impairment |
Aug, 2031
(7 years from now) | |
| US9169213 | EISAI INC | Method of weight management |
Dec, 2032
(8 years from now) | |
| US8999970 | EISAI INC | Administration of an anti-obesity compound to individuals with renal impairment |
Feb, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 27, 2017 |
Drugs and Companies using LORCASERIN HYDROCHLORIDE ingredient
NCE-1 date: 27 June, 2016
Market Authorisation Date: 27 June, 2012
Treatment: Method for chronic weight management; Method for chronic weight management by controlling weight gain; Method for chronic weight management by treating obesity; Method for chronic weight management in...
Dosage: TABLET;ORAL
BELVIQ family patents
5. Belviq Xr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6953787 | EISAI INC | 5HT2C receptor modulators |
Apr, 2023
(1 year, 10 days ago) | |
| US8367657 | EISAI INC | Processes for preparing 3-benzazepines |
Apr, 2023
(1 year, 10 days ago) | |
| US7977329 | EISAI INC | 5HT2C receptor modulators |
Apr, 2023
(1 year, 10 days ago) | |
| US8546379 | EISAI INC | 5HT2C receptor modulators |
Apr, 2023
(1 year, 10 days ago) | |
| US8697686 | EISAI INC | Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-thtrahydro-1H-3-benzazepine hydrochloride |
Dec, 2025
(1 year, 8 months from now) | |
| US8168624 | EISAI INC | Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride |
Apr, 2029
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7514422 | EISAI INC | 5HT2c receptor modulators |
Apr, 2023
(1 year, 10 days ago) | |
| US8273734 | EISAI INC | 5HT2C receptor modulators |
Apr, 2023
(1 year, 10 days ago) | |
| US8207158 | EISAI INC | 5HT2c receptor modulators |
Apr, 2023
(1 year, 10 days ago) | |
| US8575149 | EISAI INC | 5HT2C receptor modulators |
Apr, 2023
(1 year, 10 days ago) | |
| US8946207 | EISAI INC | Processes for preparing 3-benzazepines |
Jun, 2024
(a month from now) | |
| US8980881 | EISAI INC | Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride |
Dec, 2025
(1 year, 8 months from now) | |
| US10226471 | EISAI INC | Modified-release dosage forms of 5-HT2C agonists useful for weight management |
Aug, 2031
(7 years from now) | |
| US9770455 | EISAI INC | Administration of an anti-obesity compound to individuals with renal impairment |
Aug, 2031
(7 years from now) | |
| US10463676 | EISAI INC | Modified-release dosage forms of 5-HT2C agonists useful for weight management |
Aug, 2031
(7 years from now) | |
| US9169213 | EISAI INC | Method of weight management |
Dec, 2032
(8 years from now) | |
| US8999970 | EISAI INC | Administration of an anti-obesity compound to individuals with renal impairment |
Feb, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 27, 2017 |
Drugs and Companies using LORCASERIN HYDROCHLORIDE ingredient
NCE-1 date: 27 June, 2016
Market Authorisation Date: 15 July, 2016
Treatment: Method for chronic weight management by treating obesity; Method for chronic weight management by controlling weight gain; Method for chronic weight management; Method for chronic weight management in...
Dosage: TABLET, EXTENDED RELEASE;ORAL
BELVIQ XR family patents
6. Dayvigo patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8268848 | EISAI INC | Cyclopropane compound |
Sep, 2031
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10188652 | EISAI INC | Compositions and methods for treating insomnia |
Oct, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 07, 2025 |
| M(M-293) | Apr 20, 2026 |
Drugs and Companies using LEMBOREXANT ingredient
NCE-1 date: 07 April, 2024
Market Authorisation Date: 07 April, 2020
Treatment: Treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance
Dosage: TABLET;ORAL
DAYVIGO family patents
7. Halaven patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6214865 | EISAI INC | Macrocyclic analogs and methods of their use and preparation |
Jul, 2023
(8 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6469182 | EISAI INC | Intermediates in the preparation of macrocyclic analogs |
Jun, 2019
(4 years ago) | |
| US7470720 | EISAI INC | Methods and compositions for use in treating cancer |
Jun, 2019
(4 years ago) | |
| US8097648 | EISAI INC | Methods and compositions for use in treating cancer |
Jan, 2021
(3 years ago) | |
|
US6214865 (Pediatric) | EISAI INC | Macrocyclic analogs and methods of their use and preparation |
Jan, 2024
(2 months ago) | |
| USRE46965 | EISAI INC | Intermediates for the preparation of analogs of Halichondrin B |
Jan, 2027
(2 years from now) | |
|
USRE46965 (Pediatric) | EISAI INC | Intermediates for the preparation of analogs of Halichondrin B |
Jul, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-280) | Sep 13, 2025 |
| Pediatric Exclusivity(PED) | Mar 13, 2026 |
| New Indication(I-721) | Jan 28, 2019 |
| Orphan Drug Exclusivity(ODE) | Jan 28, 2023 |
| Orphan Drug Exclusivity(ODE-107) | Jan 28, 2023 |
| New Chemical Entity Exclusivity(NCE) | Nov 15, 2015 |
Drugs and Companies using ERIBULIN MESYLATE ingredient
NCE-1 date: 13 March, 2025
Market Authorisation Date: 15 November, 2010
Treatment: Treatment of patients with metastatic breast cancer
Dosage: SOLUTION;INTRAVENOUS
HALAVEN family patents
8. Lenvima patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7253286 | EISAI INC | Nitrogen-containing aromatic derivatives |
Oct, 2025
(1 year, 6 months from now) | |
| US7612208 | EISAI INC | Crystalline form of the salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or the solvate of the salt and a process for preparing the same |
Sep, 2026
(2 years from now) | |
| US11186547 | EISAI INC | High-purity quinoline derivative and method for manufacturing same |
Aug, 2035
(11 years from now) | |
| US10407393 | EISAI INC | High-purity quinoline derivative and method for manufacturing same |
Aug, 2035
(11 years from now) | |
| US10259791 | EISAI INC | High-purity quinoline derivative and method for manufacturing same |
Aug, 2035
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9006256 | EISAI INC | Antitumor agent for thyroid cancer |
Jul, 2027
(3 years from now) | |
| US11090386 | EISAI INC | Method for suppressing bitterness of quinoline derivative |
Feb, 2036
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-196) | Aug 15, 2025 |
| M(M-269) | Jul 21, 2024 |
| New Indication(I-868) | Aug 10, 2024 |
| M(M-272) | Dec 19, 2024 |
| Pediatric Exclusivity(PED) | Feb 15, 2026 |
| Orphan Drug Exclusivity(ODE) | Feb 13, 2022 |
| New Indication(I-734) | May 13, 2019 |
| Orphan Drug Exclusivity(ODE-87) | Feb 13, 2022 |
| New Indication(I-787) | Aug 15, 2021 |
| New Indication(I-807) | Sep 17, 2022 |
| New Chemical Entity Exclusivity(NCE) | Feb 13, 2020 |
Drugs and Companies using LENVATINIB MESYLATE ingredient
NCE-1 date: 15 February, 2025
Market Authorisation Date: 13 February, 2015
Treatment: Method for treating thyroid carcinoma including differentiated thyroid cancer; Treatment with lenvima by administering lenvima as a suspension
Dosage: CAPSULE;ORAL
LENVIMA family patents
9. Lusedra patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6872838 | EISAI INC | Water soluble prodrugs of hindered alcohols |
Aug, 2018
(5 years ago) | |
| US6204257 | EISAI INC | Water soluble prodrugs of hindered alcohols |
Jul, 2022
(1 year, 9 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 12, 2013 |
Drugs and Companies using FOSPROPOFOL DISODIUM ingredient
NCE-1 date: 12 December, 2012
Market Authorisation Date: 12 December, 2008
Treatment: Sedative-hypnotic agent indicated for monitored anesthesia care (mac) sedation
Dosage: SOLUTION;INTRAVENOUS
LUSEDRA family patents